<DOC>
	<DOCNO>NCT00877903</DOCNO>
	<brief_summary>The objective present study establish safety efficacy Prochymal速 follow first acute myocardial infarction .</brief_summary>
	<brief_title>Prochymal速 ( Human Adult Stem Cells ) Intravenous Infusion Following Acute Myocardial Infarction ( AMI )</brief_title>
	<detailed_description>The standard care treatment acute myocardial infarction ( AMI ) usually include immediate perfusion , optimal pain relief , oxygen , aspirin anti-coagulants , Beta-Blockers , nitrate Ace-inhibitors . However , salvage viable myocardium dependent early reperfusion , minority patient reach hospital within time-window myocardial rescue . Thus , even patient manages tobacco use , hypertension , lipid level , diabetes , weight exercise , many patient go develop Congestive Heart Failure ( CHF ) . Though medical management CHF may improve symptom slow disease progression , treatment restore function myocardium . A therapy could improve myocardial remodel process reduce incidence severity CHF follow acute MI would provide significant benefit . The characteristic biologic activity Prochymal速 , along good safety profile human trial date , suggest Prochymal速 may good candidate address unmet medical need .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Male female 21 85 year old , inclusive First heart attack within 7 day prior randomization drug infusion Baseline LVEF 2045 % Hemodynamically stable within 24 hour prior randomization Adequate pulmonary function Previous medical history heart attack , heart failure , significant valvular heart disease , aortic dissection Pacemaker device Pregnant , breastfeeding , intend become pregnant study Allergy cow pig derive product Evidence active malignancy prior history active malignancy Major surgical procedure major trauma within past 14 day Autoimmune disease ( e.g. , Lupus , Multiple Sclerosis ) Any medical condition , opinion Investigator , render participation unsuitable Undergone pharmacologic cardioversion external defibrillation within 24 hour randomization . Experienced cardiac arrest 36 hour presentation site within 24 hour randomization .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Acute myocardial infarction</keyword>
	<keyword>AMI</keyword>
	<keyword>Myocardial infarction</keyword>
	<keyword>Heart attack</keyword>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>MSC</keyword>
	<keyword>Adult human stem cell</keyword>
	<keyword>Osiris</keyword>
</DOC>